---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017778"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T19:48:29.735015+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coherus Q3 net revenue $74.6M (+27% QoQ); net loss narrows to $39.6M; LOQTORZI approved

## Summary
- Q3 2023 net revenue $74.6M, up 27% from Q2; net loss $39.6M ($0.41/sh) vs $86.7M ($1.11/sh) in Q3 2022.
- CIMERLI net sales $40.0M (+50% QoQ); UDENYCA net sales $33.0M (+4% QoQ); YUSIMRY launched with $1.4M Q3 sales.
- FDA approved LOQTORZI (toripalimab-tpzi) on Oct 27 for nasopharyngeal carcinoma; commercial launch expected Q1 2024.
- Closed Surface Oncology acquisition on Sep 8, adding clinical-stage anti-IL-27 and anti-CCR8 I-O pipeline assets.
- UDENYCA ONBODY BLA resubmitted Oct 4; potential approval late 2023 or early 2024.

## SEC filing metadata
- accession: 0001558370-23-017778
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/0001558370-23-017778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/chrs-20231106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017778
- JSON: https://secwatch.observer/filing/0001558370-23-017778.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017778.txt

## Key facts
- Earnings Releases
  Coherus Oncology, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 6, 2023, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000155837023017778/0001558370-23-017778-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.